Meningococcal Disease: A Detailed Guide

Last Updated on August 28, 2026 by Nurseslab.in Editorial Team

Overview

Meningococcal disease is an invasive infection caused by the bacterium Neisseria meningitidis, also called meningococcus. The two best-known forms are meningococcal meningitis, which inflames the membranes surrounding the brain and spinal cord, and meningococcal septicaemia or meningococcaemia, in which bacteria multiply in the bloodstream. A person may have either syndrome or both simultaneously. Less common presentations include pneumonia, septic arthritis, pericarditis, epiglottitis, conjunctivitis, and a chronic low-grade bloodstream infection.

The disease is uncommon in many vaccinated populations but remains one of the most time-critical infectious emergencies. Early symptoms may resemble influenza or another viral illness. Rapid multiplication in blood can trigger overwhelming inflammation, vascular leakage, abnormal clotting, tissue bleeding, shock, adrenal injury, and multiple-organ failure. Even with appropriate treatment, the condition can be fatal or leave permanent disability.

The Organism and Serogroups

Neisseria meningitidis is a Gram-negative diplococcus adapted to humans. It commonly colonises the nasopharynx without causing illness. Its polysaccharide capsule helps it resist immune clearance and determines the serogroup. Serogroups A, B, C, W, X, and Y cause most invasive disease worldwide, but the dominant groups vary by country, age, year, and outbreak.

The organism’s outer membrane contains endotoxin. When bacteria enter the blood, endotoxin and the immune response can injure the endothelium, activate complement and coagulation, and cause capillary leakage. This explains the combination of hypotension, petechiae or purpura, reduced blood flow to limbs and organs, and disseminated intravascular coagulation seen in severe septicaemia.

Carriage, Transmission, and Incubation

Many healthy people carry meningococci temporarily in the nose or throat. Carriage usually causes no symptoms and does not mean that the person has invasive disease. In a very small proportion, bacteria cross the mucosal barrier, enter the bloodstream, and invade the meninges or other organs.

• Route: Respiratory and throat secretions spread the organism during close or prolonged contact.
• Examples of exposure: Household living, intimate kissing, sharing a bedroom, direct exposure to saliva, or unprotected airway procedures.
• Less likely exposure: Brief casual contact, passing someone in a corridor, or being in the same building generally does not meet close-contact criteria.
• Incubation: Commonly about three to four days, with a recognised range of approximately two to ten days.
• Period of infectiousness: Effective antibiotics rapidly reduce carriage; hospitals use droplet precautions for a locally defined period after therapy begins.

Risk Factors

• Age: Infants, adolescents and young adults, and very old adults have higher rates in many settings.
• Close living: Dormitories, military accommodation, boarding schools, shelters, crowded households, and detention settings facilitate transmission.
• Complement deficiency: Deficiency of terminal complement components, properdin, factor D, or factor H increases invasive and recurrent disease risk.
• Complement-inhibitor therapy: Medicines such as eculizumab or ravulizumab cause very high risk; vaccination and preventive antibiotics do not provide complete protection.
• Absent or poorly functioning spleen: Includes surgical asplenia and functional hyposplenia.
• HIV infection and other immune compromise: These can increase acquisition or severe-disease risk.
• Microbiology work: Laboratory staff routinely exposed to meningococcal isolates require specific vaccination and exposure protocols.
• Smoking and second-hand smoke: Damage to respiratory mucosa may increase carriage and invasion risk.
• Recent respiratory infection: Viral illness can disrupt mucosal defences.
• Travel or mass gathering: Risk rises in outbreak areas, the African meningitis belt, and selected gatherings such as Hajj or Umrah.
• Outbreak membership: Students, community groups, workplaces, or populations linked epidemiologically to multiple cases may require targeted vaccination.

Clinical Syndromes

Meningococcal Meningitis

Bacteria invade cerebrospinal fluid and inflame the meninges. Typical features include fever, severe headache, neck stiffness, photophobia, vomiting, confusion, drowsiness, and seizures. The presentation may be incomplete. Meningitis can occur without the characteristic rash, and very young, older, or immunocompromised patients may lack marked neck stiffness.

Meningococcal Septicaemia

Bloodstream disease can progress more rapidly than meningitis and may occur without meningeal symptoms. Early features include fever, chills, severe muscle or limb pain, vomiting, diarrhoea, cold hands and feet, pale or mottled skin, fast breathing, and unusual sleepiness. Endotoxin-mediated vascular injury produces petechiae, purpura, shock, disseminated intravascular coagulation, adrenal failure, kidney injury, and reduced blood flow to skin and limbs.

Other Presentations

• Pneumonia: More often associated with some serogroups and older adults; may include bacteraemia.
• Septic arthritis: A hot, swollen, painful joint can be the main feature.
• Pericarditis: Infection or immune-mediated inflammation around the heart causes chest pain or haemodynamic compromise.
• Conjunctivitis: Primary meningococcal eye infection is uncommon but important because invasive disease can follow.
• Chronic meningococcaemia: Rare intermittent fever, rash, and joint symptoms over days or weeks.

Symptoms in Older Children and Adults

• Sudden fever or chills.
• Severe headache and neck stiffness.
• Nausea, vomiting, photophobia, or sound sensitivity.
• Confusion, irritability, drowsiness, or difficulty waking.
• Severe muscle, joint, abdominal, chest, or limb pain.
• Cold hands and feet, pale or mottled skin, rapid breathing, or reduced urine.
• Petechial or purpuric rash that does not fade under pressure.
• Seizure, weakness, speech difficulty, collapse, or coma.

Symptoms in Babies and Young Children

• Poor feeding, vomiting, or refusal of feeds.
• Unusual irritability, a high-pitched cry, or distress when handled.
• Floppiness, stiffness, abnormal movements, or seizures.
• Reduced interaction, marked sleepiness, or difficulty waking.
• A tense or bulging fontanelle, though this may be absent.
• Fever or an abnormally low temperature.
• Mottled, pale, or blotchy skin; cold extremities; or a non-blanching rash.
• Rapid breathing, grunting, pauses in breathing, or poor circulation.

The Rash and the “Glass Test”

A meningococcal rash may begin as tiny red, purple, or brown pinpricks and develop into larger bruise-like patches. Non-blanching means the marks do not fade when firm pressure is applied through a clear glass. This finding is an emergency, but the test has limitations: early rash can blanch, lesions may be absent, and colour changes can be difficult to see on darker skin. Check the whole body, including palms, soles, conjunctivae, inside the mouth, and less pigmented areas. Never delay emergency care to repeat the test.

Emergency Recognition and First Response

• Call emergency services immediately for suspected meningococcal disease, sepsis, altered consciousness, seizure, rapidly spreading rash, or a seriously ill baby.
• Do not wait for neck stiffness or a rash.
• Do not give food or drink to a drowsy person or someone vomiting repeatedly.
• If unconscious but breathing, place the person safely on their side if trained and monitor breathing.
• Tell clinicians about vaccination, immune disorders, complement-inhibitor use, recent antibiotics, travel, close contacts, and symptom timing.
• Pre-hospital antibiotics may be considered under local emergency protocols when transfer is not delayed.

Diagnostic Evaluation

1. Immediate assessment: Airway, breathing, circulation, oxygenation, perfusion, blood pressure, temperature, blood glucose, mental state, seizures, and signs of shock are assessed without delay.
2. Focused history: Onset, progression, rash, limb pain, headache, neck stiffness, vomiting, diarrhoea, neurological symptoms, exposure, vaccination, immune status, complement inhibitors, and recent antibiotics are documented.
3. Physical examination: Includes whole-skin inspection, capillary refill, pulse quality, mental status, neck movement, cranial nerves, focal neurology, cardiorespiratory findings, joints, and urine output.
4. Blood cultures: Taken before antibiotics when this does not delay treatment.
5. Whole-blood PCR: Nucleic-acid amplification can detect meningococcal DNA after antibiotics and supports diagnosis.
6. Routine blood tests: Full blood count, C-reactive protein, electrolytes, glucose, kidney and liver function, lactate, blood gas, and coagulation assess severity and organ injury.
7. Coagulation studies: Prothrombin time, activated partial thromboplastin time, fibrinogen, and D-dimer help identify disseminated intravascular coagulation.
8. Lumbar puncture: Cerebrospinal fluid is analysed when meningitis is suspected and the procedure is safe. Treatment must not wait if lumbar puncture is delayed.
9. Cerebrospinal fluid tests: Cell count, differential, glucose with paired blood glucose, protein, Gram stain, culture, and PCR are commonly requested.
10. Imaging: CT or MRI is reserved for focal neurological signs, severely reduced consciousness, signs of raised intracranial pressure, selected seizures, or an alternative diagnosis. Routine imaging before lumbar puncture is inappropriate.
11. Culture from another sterile site: Joint, pericardial, pleural, or other fluid may identify unusual presentations.
12. Serogroup and susceptibility testing: Public-health laboratories characterise the strain, guide outbreak control, and detect antimicrobial resistance.

When Lumbar Puncture Is Deferred

• Haemodynamic or respiratory instability requiring resuscitation.
• Severe disseminated intravascular coagulation, thrombocytopenia, or unsafe anticoagulation.
• Signs of dangerous intracranial pressure or mass effect.
• Focal neurological deficit, papilloedema, markedly reduced consciousness, or selected new-onset seizures.
• Skin infection at the puncture site or suspected spinal epidural infection.

Deferring lumbar puncture does not mean deferring treatment. Blood samples are obtained promptly, empirical antibiotics are started, and cerebrospinal fluid is reconsidered after stabilisation when it can still assist management.

Differential Diagnosis

• Pneumococcal, group B streptococcal, or other bacterial meningitis and sepsis.
• Viral meningitis or encephalitis.
• Staphylococcal or streptococcal toxic shock and severe invasive group A streptococcal disease.
• Rickettsial, leptospiral, or other infections causing fever and rash.
• Immune thrombocytopenia, leukaemia, vasculitis, or another cause of purpura.
• Severe malaria, dengue, or other travel-related infection.
• Subarachnoid haemorrhage, stroke, or metabolic encephalopathy.
• Benign viral rash; this should be diagnosed cautiously when the patient appears systemically unwell.

Immediate Treatment

• Antibiotics: Start effective intravenous therapy immediately when disease is suspected. An extended-spectrum cephalosporin such as ceftriaxone or cefotaxime is standard empirical coverage in many guidelines.
• Do not wait for tests: Blood culture, PCR, imaging, or lumbar puncture should never create an avoidable delay.
• Targeted treatment: Continue ceftriaxone or cefotaxime after confirmation, or switch to penicillin G or ampicillin only when susceptibility is established and local guidance supports it.
• Dexamethasone: May be given with or before the first antibiotic dose when bacterial meningitis is suspected, following age-specific local guidance. It is not a substitute for antibiotics.
• Infection control: Use droplet precautions until effective therapy has been given for the required interval.
• Carriage eradication: If the treatment regimen does not reliably clear nasopharyngeal carriage, an additional eradication regimen may be required before discharge.

Resuscitation and Intensive Care

• Airway and oxygen: Provide oxygen, protect the airway, and use mechanical ventilation when consciousness, breathing, or shock requires it.
• Circulation: Obtain rapid vascular access, monitor lactate and perfusion, give carefully reassessed fluid boluses, and start vasoactive medicines promptly if shock persists.
• Coagulation: Treat clinically significant bleeding and disseminated intravascular coagulation with specialist guidance; laboratory numbers alone do not determine transfusion.
• Seizures: Give emergency antiseizure treatment and consider continuous electroencephalography in persistent coma.
• Intracranial pressure: Manage ventilation, positioning, osmotic therapy, and neurosurgical interventions when indicated.
• Adrenal dysfunction: Severe bilateral adrenal haemorrhage can contribute to refractory shock and may require corticosteroid replacement.
• Kidney support: Monitor urine, electrolytes, and creatinine; dialysis may be needed for severe acute kidney injury.
• Skin and limb perfusion: Repeatedly assess pulses, temperature, colour, pressure, compartment syndrome, and tissue viability with vascular, surgical, plastic, and orthopaedic teams.
• Nutrition and pressure care: Begin appropriate enteral nutrition, eye care, skin protection, and rehabilitation planning early.

Management of Close Contacts

Public-health authorities identify people with meaningful exposure. Prophylaxis should be given as soon as possible, ideally within 24 hours of recognising the index case. Benefit becomes limited when delayed substantially. Vaccination does not replace antibiotic prophylaxis after a qualifying exposure.

• Usually eligible: Household members, childcare-room contacts, intimate partners, and people directly exposed to oral or respiratory secretions during the infectious period.
• Healthcare exposure: Unprotected mouth-to-mouth ventilation, intubation, suctioning, or close airway examination may qualify. Routine care without secretion exposure generally does not.
• Common prophylactic options: Rifampicin, ceftriaxone, or ciprofloxacin are used according to age, pregnancy, contraindications, drug interactions, susceptibility, and local resistance. Azithromycin may be preferred in selected resistance settings.
• Not routine: Casual school, workplace, transport, or social contacts usually do not need antibiotics unless outbreak assessment says otherwise.
• Symptom vigilance: Contacts must seek urgent care if symptoms develop because prophylaxis is not completely protective.

Vaccination

Vaccination is the most effective long-term prevention strategy. Products and schedules differ by country and age. Conjugate vaccines protect against serogroups A, C, W, and Y; separate protein-based vaccines protect against serogroup B; some countries now use combined products. No vaccine covers every meningococcal strain.

• Follow the routine national infant, adolescent, or young-adult schedule.
• Give risk-based vaccination for asplenia, complement deficiency, complement-inhibitor therapy, HIV where recommended, microbiology exposure, travel, or outbreak risk.
• Administer booster doses when ongoing risk persists.
• Verify destination-specific requirements before Hajj, Umrah, or travel to epidemic regions.
• Continue urgent symptom assessment regardless of vaccination status; breakthrough disease can occur.
• Use public-health-directed vaccination during outbreaks based on the strain and population at risk.

Complications

• Hearing loss: Can be unilateral or bilateral and may appear during recovery.
• Neurological injury: Seizures, epilepsy, stroke, weakness, coordination difficulty, cranial nerve palsy, hydrocephalus, or cognitive impairment.
• Skin and limb damage: Purpura fulminans can cause deep scarring, growth disturbance, tissue necrosis, or amputation.
• Organ failure: Acute kidney injury, respiratory failure, cardiac dysfunction, liver injury, and disseminated intravascular coagulation.
• Adrenal haemorrhage: Waterhouse–Friderichsen syndrome causes severe adrenal failure and shock.
• Orthopaedic consequences: Growth-plate injury, contracture, chronic pain, and prosthetic needs may follow limb ischaemia.
• Psychological effects: Anxiety, depression, post-traumatic symptoms, grief, altered body image, and fear of recurrence can affect patients and families.
• Death: The infection can be fatal despite rapid and appropriate treatment.

Recovery and Follow-Up

Recovery can be rapid after uncomplicated meningitis or prolonged after septicaemic shock. Fatigue, weakness, headache, poor sleep, reduced concentration, dizziness, pain, and emotional distress may continue after discharge. Rehabilitation should begin in hospital and continue according to functional need.

• Arrange prompt hearing assessment and repeat it if concerns arise.
• Review neurological function, seizures, vision, balance, speech, swallowing, cognition, and behaviour.
• Assess scars, wounds, limb perfusion, pain, mobility, prosthetic needs, and growth in children.
• Monitor kidney, cardiac, respiratory, and endocrine recovery after organ failure.
• Review school, work, driving, and daily-living needs with graded return plans.
• Offer physiotherapy, occupational therapy, speech therapy, neuropsychology, audiology, psychological care, and social support.
• Evaluate complement deficiency or another immune disorder after recurrent disease, unusual strains, or suggestive history.
• Provide a written summary of the organism, serogroup, treatment, prophylaxis, vaccination, and warning signs.

Prognosis

Outcome depends on the clinical syndrome, organism strain, age, immune status, speed of antibiotics, severity of shock, coagulation failure, neurological involvement, and access to intensive care. Current public-health information commonly reports death in approximately 10% to 15% of invasive cases, while up to one in five survivors has a long-term disability. Septicaemia with shock and extensive purpura generally carries a worse immediate prognosis than meningitis without bloodstream collapse.

Survival statistics describe populations, not a specific individual. A person who initially appears to recover well may later show hearing, cognitive, educational, emotional, or physical consequences. Planned follow-up is therefore part of treatment.

Prevention Beyond Vaccination

• Practise hand and respiratory hygiene and dispose of tissues promptly.
• Avoid sharing drinks, smoking devices, lip products, toothbrushes, or utensils that contact saliva.
• Reduce exposure to tobacco smoke.
• Seek early medical assessment for compatible symptoms, especially during an outbreak.
• Ensure close contacts receive public-health advice promptly rather than waiting for symptoms.
• People taking complement inhibitors should maintain vaccination, follow any prescribed antibiotic plan, carry treatment information, and seek immediate care for symptoms even when vaccinated.
• Laboratories should follow biosafety and post-exposure procedures for aerosol-generating work with isolates.

Public-Health Surveillance and Outbreak Control

Invasive meningococcal disease is usually notifiable. Rapid laboratory confirmation, serogrouping, and genomic typing help identify linked cases, resistance, and outbreaks. Public-health teams define the population at risk, coordinate prophylaxis, decide whether targeted vaccination is needed, communicate with schools or communities, and monitor for additional cases. Broad community antibiotics are generally not used because they create adverse effects and resistance without reliably controlling an outbreak.

Common Misconceptions

• “There must be a rash.” False. Meningitis and early septicaemia may occur without one.
• “A negative glass test rules it out.” False. Early lesions can blanch and a rash may develop later.
• “Vaccinated people cannot get it.” False. Vaccines are highly valuable but do not cover every strain or prevent every case.
• “Everyone in the same school needs antibiotics.” False. Prophylaxis is based on defined close exposure and public-health assessment.
• “A lumbar puncture must happen before treatment.” False. Antibiotics must not be delayed when the procedure is unsafe or unavailable immediately.
• “Meningitis and meningococcal disease are the same.” False. Meningococcus can cause meningitis, bloodstream infection, or other invasive syndromes; meningitis has many other causes.

Key Points

Meningococcal disease is an invasive infection caused by Neisseria meningitidis. It most commonly presents as meningitis, septicaemia, or both and can deteriorate within hours. A rash may be absent, so emergency recognition depends on the whole clinical picture. Diagnosis uses blood culture, PCR, and, when safe, cerebrospinal fluid testing. Intravenous antibiotics and resuscitation begin immediately without waiting for full confirmation. Public-health notification, close-contact prophylaxis, carriage eradication when needed, vaccination, and structured survivor follow-up are essential parts of care.

Sources for Further Reading

• Centers for Disease Control and Prevention: Clinical Overview and Clinical Guidance for Meningococcal Disease.
• World Health Organization: Meningitis fact sheet and guidance on diagnosis, treatment, and care.
• National Institute for Health and Care Excellence: Bacterial meningitis and meningococcal disease—recognition, diagnosis, and management.
• Local public-health guidance on vaccination, chemoprophylaxis, antimicrobial resistance, and outbreak control.

Nursing Care of a Patient with Menometrorrhagia

Overview

Menometrorrhagia is abnormal uterine bleeding characterized by menstrual bleeding that is both heavy or prolonged and irregular or more frequent than normal. It may be related to ovulatory dysfunction, hormonal imbalance, uterine fibroids, polyps, adenomyosis, endometrial hyperplasia, pregnancy-related complications, pelvic infection, thyroid disease, bleeding disorders, medications such as anticoagulants, intrauterine devices, or malignancy. Nursing care focuses on assessing bleeding severity, maintaining haemodynamic stability, preventing or treating anaemia, identifying urgent causes, supporting diagnostics and treatment, and providing education for follow-up and recurrence prevention.

Nursing Assessment

• Assess bleeding pattern, including onset, duration, frequency, number of pads or tampons used, passage of clots, flooding, bleeding between periods, postcoital bleeding, and impact on daily activities.
• Assess haemodynamic status: blood pressure, heart rate, orthostatic symptoms, pallor, dizziness, syncope, fatigue, shortness of breath, chest discomfort, capillary refill, and level of consciousness.
• Review menstrual, obstetric, gynaecological, sexual, and contraceptive history, including last menstrual period, possibility of pregnancy, miscarriage symptoms, ectopic pregnancy risk, and postmenopausal bleeding.
• Assess associated symptoms such as pelvic pain, cramping, fever, foul discharge, dyspareunia, urinary symptoms, weight change, bruising, gum bleeding, headaches, thyroid symptoms, or symptoms of anaemia.
• Review medications and risk factors, including anticoagulants, antiplatelets, hormonal therapy, emergency contraception, intrauterine device use, steroids, herbal products, bleeding disorders, liver disease, renal disease, thyroid disease, obesity, polycystic ovary syndrome, and family history of gynaecological cancer.
• Review diagnostic results when available, including pregnancy test, complete blood count, ferritin or iron studies, coagulation tests, thyroid function, pelvic ultrasound, Pap test, infection testing, endometrial biopsy, and other provider-ordered investigations.
• Assess emotional distress, embarrassment, school or work disruption, sexual health concerns, cultural needs, access to menstrual products, financial barriers, and ability to attend follow-up care.

Priority Nursing Diagnoses

• Risk for deficient fluid volume related to excessive or prolonged uterine bleeding.
• Risk for ineffective tissue perfusion related to acute blood loss or severe anaemia.
• Fatigue related to iron-deficiency anaemia, ongoing blood loss, sleep disruption, or pain.
• Acute pain related to uterine cramping, pelvic pathology, infection, or associated gynaecological condition.
• Risk for infection related to pelvic inflammatory disease, retained products of conception, procedures, or prolonged bleeding.
• Anxiety related to heavy irregular bleeding, fear of serious illness, fertility concerns, or diagnostic uncertainty.
• Deficient knowledge related to bleeding tracking, medication use, anaemia prevention, warning signs, and follow-up needs.

Nursing Interventions

• Monitor vital signs, bleeding amount, pad counts, clot size, pain, urine output, pallor, dizziness, shortness of breath, and level of consciousness.
• Escalate care urgently for haemodynamic instability, syncope, severe abdominal or pelvic pain, suspected pregnancy complication, soaking one or more pads per hour for several hours, large clots, severe anaemia symptoms, fever, or postmenopausal bleeding.
• Maintain intravenous access, administer fluids, oxygen, blood products, iron therapy, tranexamic acid, hormonal therapy, antibiotics, analgesics, or antiemetics as prescribed.
• Support diagnostic evaluation by preparing the patient for pregnancy testing, pelvic examination, blood tests, ultrasound, endometrial sampling, infection testing, or specialist gynaecology review.
• Administer prescribed medications correctly and monitor for effectiveness and adverse effects, including nausea, thromboembolism warning signs with hormonal therapy, gastrointestinal effects with iron, and bleeding changes with anticoagulants.
• Promote iron replacement and nutrition with iron-rich foods such as lean meat, fish, poultry, beans, lentils, spinach, fortified cereals, and vitamin C sources to support absorption.
• Encourage rest during heavy bleeding, activity pacing, fall precautions if dizzy, and assistance with activities of daily living when anaemia is significant.
• Provide privacy, respectful communication, menstrual products, emotional support, and culturally sensitive education to reduce embarrassment and improve reporting accuracy.
• Coordinate care with gynaecology, primary care, haematology, endocrinology, dietetics, social work, and emergency services depending on the suspected cause and severity.

Patient and Family Education

• Explain that menometrorrhagia means menstrual bleeding that is heavy or prolonged and also irregular or unpredictable.
• Teach the patient to track bleeding using a menstrual diary, including dates, pad or tampon counts, clots, pain, dizziness, fatigue, and medicines taken.
• Encourage taking prescribed medicines exactly as directed, including iron, hormonal therapy, tranexamic acid, antibiotics, or pain relief, and not stopping treatment without advice.
• Teach iron-rich nutrition and ways to improve iron absorption, such as taking iron with vitamin C when appropriate and avoiding tea, coffee, or calcium at the same time as iron if advised.
• Review urgent warning signs: soaking one or more pads per hour for several hours, fainting, severe dizziness, chest pain, shortness of breath, severe pelvic pain, fever, foul discharge, pregnancy possibility with bleeding, large clots, or any postmenopausal bleeding.
• Encourage follow-up appointments, repeat blood tests, ultrasound, biopsy, or specialist review as ordered to identify the cause and prevent recurrence.
• Provide reassurance, privacy, culturally sensitive communication, and information about access to menstrual products, financial support, or community services if needed.

Expected Outcomes

• The patient maintains stable vital signs and shows no signs of haemodynamic instability.
• Bleeding decreases or is controlled according to the treatment plan.
• Haemoglobin, ferritin, and iron status improve or remain stable according to individualized goals.
• The patient reports reduced fatigue, dizziness, pain, anxiety, and disruption to daily activities.
• The underlying cause is investigated and managed through appropriate follow-up and referral.
• The patient and family explain medication use, bleeding tracking, anaemia prevention, urgent warning signs, and follow-up needs.

Evaluation

Evaluate nursing care by reviewing bleeding pattern, pad counts, clot passage, vital signs, pain, dizziness, fatigue, haemoglobin or ferritin trends, medication response, side effects, diagnostic results, emotional well-being, and follow-up attendance. Revise the care plan if bleeding worsens, anaemia persists, pregnancy-related bleeding is suspected, infection signs occur, postmenopausal bleeding is present, or the patient has barriers to treatment, monitoring, or specialist care.

REFERENCES

1. Parikh SR, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, Safadi MA, Shao Z, Zhu B, von Gottberg A, Borrow R, Ramsay ME, Ladhani SN. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020 Oct;81(4):483-498. doi:10.1016/j.jinf.2020.05.079
2. Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women (https://pubmed.ncbi.nlm.nih.gov/26254516/). Am J Obstet Gynecol. 2016 Jan;214(1):31-44.
3. Davis E, Sparzak PB. Abnormal Uterine Bleeding (https://www.ncbi.nlm.nih.gov/books/NBK532913/). 2023 Sep 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
4. Merck Manual. Abnormal Uterine Bleeding (AUB). (https://www.merckmanuals.com/home/women-s-health-issues/menstrual-disorders-and-abnormal-vaginal-bleeding/abnormal-uterine-bleeding-aub) Last reviewed 2/2023.
5. Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions (https://pubmed.ncbi.nlm.nih.gov/30198563/). Int J Gynaecol Obstet. 2018 Dec;143(3):393-408. 
6. Mbaeyi SA, Joseph SJ, Blain A, Wang X, Hariri S, MacNeil JR. Meningococcal Disease Among College-Aged Young Adults: 2014-2016. Pediatrics. 2019 Jan;143(1):e20182130. doi:10.1542/peds.2018-2130
7. The American College of Obstetricians and Gynecologists. Abnormal Uterine Bleeding (https://www.acog.org/womens-health/faqs/abnormal-uterine-bleeding). Last updated 12/2021.
8. Whitaker L, Critchley HO. Abnormal uterine bleeding (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970656/). Best Pract Res Clin Obstet Gynaecol. 2016 Jul;34:54-65. 

Stories are the threads that bind us; through them, we understand each other, grow, and heal.

JOHN NOORD

Connect with “Nurses Lab Editorial Team”

I hope you found this information helpful. Do you have any questions or comments? Kindly write in comments section. Subscribe the Blog with your email so you can stay updated on upcoming events and the latest articles.